De Novo device
Aptima Trichomonas Vaginalis Assay - Panther
Gen-Probe, Inc. · Trichomonas Vaginalis Nucleic Acid Amplification Test System (OUY, Class II) · First FDA decision Apr 19, 2011, newest Jan 9, 2013HIV, hepatitis and sexually transmitted infections
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
10
Naming "Aptima"
MAUDE reports
1,048
Brand "Aptima", since 2015
PubMed studies
675
Mentioning "Aptima"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Aptima Trichomonas Vaginalis Assay - Panther
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K122062 · Decided Jan 9, 2013 · 180 days after receipt
Device type: Trichomonas Vaginalis Nucleic Acid Amplification Test System (OUY) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs)Local determinationIn effectL38227First Coast Service Options, Inc.Updated Oct 20, 2023
- Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs)Local determinationIn effectL38229Novitas Solutions, Inc.Updated Oct 20, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Aptima", any status and sponsor, newest update first.
- Self-taken Penile Meatal Swabs for Chlamydia, Gonorrhoea and Mycoplasma Genitalium DetectionStatus unknown
The Leeds Teaching Hospitals NHS TrustAcademic, hospital or other
NCT04244994 · 2,400 participants (planned) · Start Apr 2020 · Primary completion Aug 2021
Device: Aptima-Combo2 and Aptima Mgen · For: Sexually Transmitted Diseases, Bacterial
Sites: Leeds, United Kingdom
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Aptima", and for the whole product code for context.
This brand
1,048 reports: 874 malfunction, 172 injury, 0 death
Whole product code OUY
30 reports: 25 malfunction, 5 injury, 0 death
Newest reports for this brand
- Aptima Combo 2 AssayInjury
2024800-2026-00082 · Received Oct 23, 2026 · Event dated Oct 5, 2026
Device type: Dna-Reagents, Neisseria (LSL)
Device problem as coded: False Negative Result; False Positive Result
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Aptima"[tiab]. The summary above synthesizes these.
- Performance evaluation of the Aptima CMV quant assay using plasma and non-plasma samples.
Lima A, Healer V, Rowe L, et al. · J Clin Virol · 2023Research Support, Non-U.S. Gov't
- Aptima HPV Genotypes in Abnormal Cervical Samples in Different Age Groups - Implication on Vaccination Strategies.
Al-Awadhi R, AlRoomy M, Dashti H, et al. · J Cytol · 2024
- Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis.
Figueiredo D, Ribeiro I, Penedones A, et al. · BMC Womens Health · 2023Research Support, Non-U.S. Gov't
- Aptima HR-HPV Testing of Cytology Specimens Is an Effective Supplement for p16 Staining to Improve Diagnostic Accuracy for HPV-Related Oropharyngeal Squamous Cell Carcinoma.
Yang X, Hu C, Zhao H, et al. · Acta Cytol · 2023
- APTIMA® Trichomonas vaginalis, a transcription-mediated amplification assay for detection of Trichomonas vaginalis in urogenital specimens.
Chapin K, Andrea S · Expert Rev Mol Diagn · 2011Review
- Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
Arbyn M, Simon M, de Sanjosé S, et al. · Lancet Oncol · 2022Meta-Analysis, Systematic Review
- Human papillomavirus testing using HPV APTIMA® assay and an external cellularity control in self-collected samples.
Pasquier C, Raymond S, Duchanois D, et al. · J Med Virol · 2023Research Support, Non-U.S. Gov't
- Evaluation of Aptima Zika Virus Assay.
Ren P, Ortiz DA, Terzian ACB, et al. · J Clin Microbiol · 2017Evaluation Study
- Aptima HIV-1 Quant Dx--A fully automated assay for both diagnosis and quantification of HIV-1.
Nair SV, Kim HC, Fortunko J, et al. · J Clin Virol · 2016Research Support, Non-U.S. Gov't
- Evaluation of the Aptima HCV Quant Dx Assay Using Serum and Dried Blood Spots.
Weber J, Sahoo MK, Taylor N, et al. · J Clin Microbiol · 2019Comparative Study, Evaluation Study
- Correction: Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis.
Figueiredo D, Ribeiro I, Penedones A, et al. · BMC Womens Health · 2024Published Erratum
- Performance evaluation of the Aptima HIV-1 Quant Dx assay for detection of HIV in infants in Kenya.
Mwau M, Mbugua J, Danda J, et al. · J Clin Virol · 2020Evaluation Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code OUY.
- Xpert TVCepheid · 510(k) 2016
- Aptima Trichomonas vaginalis AssayHologic, Inc. · 510(k) 2023
- BD MAX CTGCTV2, BD MAX SystemBecton, Dickinson and Company · 510(k) 2019
- Bd Max Ct/Gc/Tv, Bd Max InstrumentBecton, Dickinson and Company · 510(k) 2016
- Solana Trichomonas AssayQuidel Corporation · 510(k) 2016
- AmpliVue Trichomonas AssayQuidel Corporation · 510(k) 2015
- Bd Probetec Trichomonas Vaginalis (Tv) Qx Amplified Dna AssayBecton, Dickinson & CO · 510(k) 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.